Research Summary: The following information is provided for research context only.
Tirzepatide is a synthetic dual-receptor agonist peptide that binds two incretin receptors at once — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both receptors are widely studied in in-vitro metabolic and endocrine research, making this compound a useful reference tool for receptor-signaling studies.
In preclinical laboratory models, tirzepatide has been examined for receptor-binding affinity, downstream cAMP and insulinotropic signaling, and comparative agonist activity. Because it targets both the GIP and GLP-1 pathways simultaneously, it offers a model for characterizing how dual-receptor activation differs from single-receptor approaches.
This vial contains lyophilized Tirzepatide at high purity, verified by independent, third-party analytical testing.
Reviews
There are no reviews yet.